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Recent chemokine receptor struc-
tures indicate that oligomerization of
chemokines, which is important for
chemokine–GAG interactions, is
incompatible with receptor binding.
Receptor–ligand structures are incom-
patible with a model of direct presen-
tation of ligand bound to GAGs.
Recent in vivo data suggest that antic-
hemokine antibodies targeting chemo-
kines in ‘soluble phase’, rather than
attached to GAGs, can be more effec-
tive in ameliorating certain inflamma-
tory conditions.Recruitment of immune cells from the vasculature relies on the presentation
of glycosaminoglycan-bound chemokines on the luminal side of vascular
endothelial cells. However, the current model of chemokine–glycosamino-
glycan interactions, and its implications for receptor interactions, remains
poorly developed. We propose a refined ‘Chemokine Cloud’ model, arguing
that chemokines are not presented to leukocytes bound to glycosamino-
glycans, but rather, in solution while sequestered within the hydrated gly-
cocalyx. We posit that glycosaminoglycans provide an immobilized
chemokine depot maintaining a ‘cloud’ of ‘solution-phase’ chemokines
within the glycocalyx, and that it is this soluble form of any given chemokine
that interacts with leukocyte-bound receptors. Our proposition clarifies
certain anomalies associated with the current model of chemokine–
glycosaminoglycan interactions, with implications for the design of blockers
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The molecular and cellular events involved in mammalian leukocyte migration can be divided
into two major sequential processes: the leukocyte adhesion cascade (see Glossary)
followed by the transendothelial migration of leukocytes from the vasculature into the
surrounding tissue [1] (summarized in Figure 1). The initial phase of the adhesion cascade
relies on interactions between selectins and selectin ligands, which cause leukocytes to roll
along the endothelium, despite the rapid blood flow in post-capillary venules. The reduced
velocity enables the marginalized leukocytes to sample the endothelial surface for positional
cues and to decide whether to re-enter the circulation or commit to transendothelial migration
from the vasculature into the surrounding tissue. Crucial to the positional information, which
ensures that leukocytes exit the vasculature at the correct point in space and time, are
chemokines, presented on the luminal side of endothelial surfaces, as well as their cognate
chemokine receptors, on marginalized leukocytes [2].
Recent mouse-based studies have shown that chemokine receptors represent a key compo-
nent of the cellular address code that ensures migration of cells to specific destinations under
both homeostatic and inflammatory conditions [3]. For example, leukocytes bearing the
chemokine receptor CCR10 will recognize its cognate ligands within the vasculature of the
skin; leukocytes bearing CCR9 will recognize its ligand in the vasculature of the gut [4]; and
CCR7 is an essential marker of cells destined for migration to secondary lymphoid organs,
defining it as a component of vertebrate homeostatic leukocyte address codes [5]. Under
inflammatory conditions, leukocytes express multiple chemokine receptors and respond to472 Trends in Immunology, June 2019, Vol. 40, No. 6 https://doi.org/10.1016/j.it.2019.03.009
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Glossary
Axonal pathfinding: process by
which neurons send out axons to
interact with the correct targets.
Beta-sheet fold: protein secondary
structural motif comprising a variable
number of connected beta strands
between three and ten amino acids
in length.
‘Bridge’ model: classic model of
direct GAG-bound chemokine
presentation to cognate receptors on
leukocytes.
CC chemokine dimers: CC
chemokines form elongated, dimeric
structures, with the individual
monomers interacting at the N-
terminal region.
Chemokines: small proteins
belonging to an evolutionarily
conserved family regulating leukocyte
recruitment to, and movement within,
resting and inflamed tissues.
Chemokine oligomerization:
chemokines form electrostatic
oligomers, most prominently seen
with inflammatory chemokines. These
can generate homo- or hetero-
oligomers, often giving rise to
structures with molecular weights in
excess of 1 MDa.
Chemokine receptors: members of
the G-protein-coupled receptor
family that bind chemokines,
mediating their biological functions.
Classical chemokine fold:
chemokine tertiary structure typically
incorporates a flexible N terminus, a
3-stranded beta sheet and a C-
terminal alpha-helix. The overall
tertiary structure is maintained by
two disulfide bonds (one in the case
of XCL1).
‘Cloud’ model: model proposing
that chemokines are not presented
directly as GAG-bound entities, but
in solution phase at the glycocalyx as
a result of dissociation from GAG-
maintained depots.
CXC chemokine dimers: CXC
chemokines form tight, dimeric
structures through interactions
between the first beta strands of the
two monomeric units.
Evasins: proteins produced by ticks
that bind and neutralize chemokine
function. They enable feeding on the
host without triggering immune and/
or inflammatory responses.
Filopodia: finger-like, probing,
cellular extensions from cells. In
leukocytes, these are involved in
(A)
(B) (C)
(D)
Figure 1. The Leukocyte Adhesion Cascade. This illustration depicts the classic leukocyte adhesion cascade model
showing the steps involved in leukocyte recruitment from the vasculature. The steps include: (A) selectin-mediated
tethering of leukocytes to the endothelial cell surface; (B) leukocyte rolling along the endothelial cell surface mediated by the
transient, and reversible, nature of the selectin–selectin ligand interactions. These interactions enable leukocytes to
‘sample’ the endothelial surface for cognate chemokine ligands (shown in yellow); (C) leukocyte tight adhesion to the
endothelial cell surface mediated by chemokine-dependent inside-out signaling and integrin activation. The activated
integrins then bind avidly to their ligands on the endothelial cell surface; and (D) transendothelial migration of leukocytes
through the endothelial layer to the subluminal tissue.locally presented chemokines on the luminal face of endothelial cells in inflamed tissues. In this
way, the specificity of cellular homing is achieved.
In both homeostatic and inflammatory contexts, the primary role for luminally presented
chemokines is to mediate ‘inside-out signaling’ [1], via their cognate receptors on leuko-
cytes, thereby activating cell surface integrins and facilitating tight binding of the cell to the
endothelial surface. This is an essential prerequisite for transendothelial migration, whereby
chemokines function specifically to induce high-affinity integrin-dependent binding of leuko-
cytes at the precise point of transendothelial migration.
An essential component of this process is the immobilization of chemokines on endothelial
surfaces through interactions with glycosaminoglycans (GAGs) [6]. Here, we present a new
refinement of the leukocyte adhesion cascade, with a specific focus on chemokine presentation
on endothelial cell surfaces. We begin with a description of the ideas that led to the current
‘bridge’ model, where chemokine oligomers simultaneously bind to receptors on leukocytes
and GAGs on endothelial cells in order to initiate cell adhesion. This is followed by new
observations that suggest that the current model is incorrect, and we propose a refined
‘cloud’ model. Our new model not only informs our understanding of a crucial aspect of
leukocyte homing in health and disease, but also highlights a novel concept that may be central
to the development of selective blockers of in vivo chemokine activity (including antibodies) for
therapeutic purposes.
Current ‘Bridge’ Model of Chemokine Presentation in the Leukocyte
Adhesion Cascade
An early concern regarding the role of chemokines in the adhesion cascade was how to
maintain their local presentation in the presence of powerful shear flow in post-capillaryTrends in Immunology, June 2019, Vol. 40, No. 6 473
detecting pathogens, and probably
respond to chemokines.
Glycocalyx: hydrated and
continuous structure on endothelial
cell surfaces; rich in proteoglycans,
glycoproteins, and glycolipids.
Glycosaminoglycans (GAGs):
highly hydrated, branched
oligosaccharides; typically extensively
sulfated. They form the sugar-rich
portion of proteoglycans.
Haptotactic signal: chemotactic
signal presented in a 2D extracellular
matrix or cell surface-bound form.
Inside-out signaling: process by
which cytoplasmic signaling
downstream of ligated receptors (e.
g., chemokine receptors) can trigger
the conformational activation and
clustering of cell surface molecules
(e.g., integrins) to mediate high-
affinity interactions with their ligands.
Interstitial: within the tissue rather
than the vasculature.
Leukocyte adhesion cascade:
model of leukocyte entry from thevenules, where transendothelial migration takes place. In principle, shear flow precludes
chemokines functioning as soluble chemoattractants in plasma, because they would rapidly
diffuse away from the source [7]. This concern led to the now widely accepted paradigm that
chemokines are anchored to the luminal face of the endothelial layer through high-affinity
binding to the GAG chains of cell surface proteoglycans [6]. These interactions allow specific
chemokines to be presented on endothelial cells at the precise anatomical position where
selective leukocyte recruitment is required.
Some years ago, biochemical and in vitro analyses of chemokine–GAG interactions provided
the first evidence that interleukin (IL)-8 (now referred to as CXCL8) forms a GAG-immobilized
haptotactic signal on endothelial cell surfaces [8]. Further concrete evidence for this interac-
tion was provided by a study describing the ability of GAG binding-deficient chemokine mutants
to recruit cells into the peritoneal cavity of mice [9]. This study showed that these chemokine
variants were able to bind and activate their receptors in vitro; however, they were unable to
elicit cell recruitment in vivo [9]. This work, as well as other analyses [10–12], supported the idea
that binding to GAGs was a prerequisite for the activity of many chemokines in vivo; it also
implied that the active form of a chemokine would be that which is bound to GAGs. This
concept became an accepted aspect of the leukocyte adhesion cascade model in the field.
However, the precise nature of the chemokine–GAG interactions, especially how these facilitate
receptor engagement, remained to be defined. Key questions relevant to this mechanism are
addressed here.vasculature into the tissue.
Proteoglycan: protein core heavily
decorated with GAGs; typically found
projecting from cell surfaces; form a
key component of the glycocalyx.
RIP-LCMV mice: transgenic animals
expressing the glycoprotein of the
lymphocytic choriomeningitis virus
(LCMV) in b cells (islets of
Langerhans), driven by the rat insulin
promoter (RIP). Infection with LCMV
Armstrong results in infiltration of
glycoprotein-specific T cells in islets
and ensuing autoimmunity against b
cells; the symptoms mimic human
type I diabetes.
Shear flow: dynamic flow of fluid
within the vasculature, as a
consequence of cardiac activity andAre GAG-Bound Chemokines Presented to Receptors, or Are Chemokines Donated to
Receptors from Their Gag Partners?
Given that chemokines can bind to both receptors and GAGs, it was not clear whether
chemokines anchored to GAGs could simultaneously bind receptors (Figure 2) or whether
they were released from GAGs and effectively donated to receptors on passing leukocytes.
Of relevance to this question are numerous studies demonstrating that, unlike cytokines,
such as members of the Fibroblast Growth Factor (FGF) family, which require GAGs for their
biological activity [13], chemokines interact with their receptors in the absence of GAGs in
vitro. Indeed, atomic resolution structures of ternary complexes between FGF, FGF recep-
tor ectodomain, and heparin/GAG exist [14], but whether chemokines also form ternary
(GAG–chemokine–receptor) or only binary (GAG–chemokine and receptor–chemokine)
complexes is currently not understood. This point is addressed in our refined model, as
discussed later.vessel diameter.
Transcytosis: transcellular transport;
here, direct movement of
chemokines from the subluminal to
luminal face of the endothelium
surrounding the vasculature.
Transendothelial migration: cell
movement from the lumen of the
vasculature through the endothelial
cell layer and into the subluminal
tissue.Do GAGs and Receptors Compete for the Same Binding Site on Chemokines?
Many studies have demonstrated significant overlap between the GAG-binding and receptor-
binding sites on several chemokines [15–19]. In agreement with such observations, using
classical in vitro receptor-binding assays, a number of studies have reported the ability of
soluble GAGs to compete with receptors for binding of chemokines and, thus, to being
capable of neutralizing chemokine function in vitro [6]. Structural studies have also shown that
the human chemokine XCL1 exists in two distinct structural folds, the classical chemokine
fold, which is involved in receptor binding, and an entirely different beta-sheet fold, which
binds to GAGs [20]. Collectively, these studies suggest that chemokine interactions with
receptors and GAGs involve the same amino acids on the chemokine surface and, thus,
cannot occur simultaneously. Therefore, it seems unlikely that single subunits of chemokines
are presented to receptors in the GAG-bound form. The question is, what other models might
explain the data?474 Trends in Immunology, June 2019, Vol. 40, No. 6
Figure 2. The ‘Bridge’ Model of Receptor–Chemokine–Glycosaminoglycan (GAG) Interactions. This illus-
tration depicts the current ‘bridge’ model in which chemokines (shown in yellow) are presented in a GAG-bound manner
to receptors on passing leukocytes. In this model, chemokines bind simultaneously to GAGs on endothelial cell surfaces
and receptors on leukocytes. The receptor is depicted as a 7-transmembrane spanning black structure on the
leukocyte.Does Chemokine Oligomerization Enable Presentation of Chemokines to Receptors in a
GAG-Bound Form?
It has been known for years that most chemokines reversibly oligomerize in solution [21–23].
Chemokine oligomers are also stabilized by their interaction with GAGs, and GAG interactions
can promote higher order chemokine oligomerization [6,24]. As a highly conserved feature
of many chemokines, oligomerization is likely to have some functional significance. That it
contributes to the affinity of chemokines for GAGs is now indisputable, as demonstrated by in
vitro biochemical and biophysical studies [25]. However, given that single chemokine sub-
units cannot simultaneously bind receptors and GAGs, chemokines have been proposed to
oligomerize in order to bind both GAGs on endothelial cells, and receptors on leukocytes,
using different subunits of chemokine oligomers [9]. Indeed, this ‘bridge’ model, whereby
chemokine oligomers ‘bridge’ two cell surfaces, became the paradigm for chemokine
presentation in the leukocyte adhesion cascade. Moreover, it has remained in place for
some time, despite no concrete evidence of its validity. New observations have now made us
reconsider this model.Trends in Immunology, June 2019, Vol. 40, No. 6 475
New Observations and Considerations Challenging the Current ‘Bridge’
Model of Chemokine Presentation
A number of observations suggest that the ‘bridge’ model of chemokine presentation by GAGs
to their receptors is not correct.
Structures of Receptor–Chemokine Complexes Do Not Support Simultaneous Binding of
an Oligomerized Chemokine by a Receptor and a GAG
The first clues that oligomerized chemokines could not simultaneously bind receptors and
GAGs(the ‘bridge’ model) were provided by in vitro receptor-binding analyses indicating that
CC chemokine dimers had no measurable affinity for their receptors [26]. When the first
structure of a receptor–chemokine complex was solved, the reason became clear: the receptor
interacts with chemokine monomers in a manner that mimics the CC chemokine dimer
interface and, thus, binding of a CC dimer to its receptor is prevented because of steric
incompatibility [27]. Although CXC chemokine dimers can bind receptors [28], our recent
preliminary results from experimental and modeling studies of CXCR4–CXCL12 suggest that
not only does receptor binding to CXCL12 compete with CXCL12 dimer formation, but there
also appears to be insufficient binding surface on the chemokine to accommodate both
receptor and GAG in a CXCR4–CXCL12 dimer complex. Although these results are preliminary
and warrant further validation, the prevailing ‘bridge’ model does not seem to adequately
explain the GAG-based endothelial presentation of chemokines in the vasculature.
The In Vivo Efficacy of Blocking Antibodies Is Inconsistent with the Concept of GAG-Bound
Chemokines Being the ‘Active’ Chemokine Form
The chemokine CXCL10 is important for T cell recruitment in a range of immune and inflam-
matory diseases [2] including Behçet’s disease [29], type 1 diabetes [30], and certain autoim-
mune conditions [31]. Thus, it has been identified as an excellent potential therapeutic target in
these disease contexts. In a recent study, the ability of two anti-CXCL10 antibodies to
ameliorate CXCL10-mediated pathology in the RIP-LCMV mouse model of type 1 diabetes
was evaluated [32]. While one of the antibodies (clone 1F11) was efficacious in curbing disease
symptoms, the second (clone 1B6) was found to be almost ineffective. Further characterization
in vitro demonstrated that the effective antibody, 1F11, could only recognize free (unbound)
chemokine (but not GAG-bound chemokine), while the antibody showing little effect in vivo
(1B6) recognized both GAG-bound and free chemokines [32]. Of note, the ineffective antibody
1B6 was in fact a more potent inhibitor of CXCL10 in in vitro cell migration assays, where all
chemokines were in free solution, compared with 1F11. However, since this antibody (1B6)
recognized GAG-bound chemokine (the most abundant form), we surmised that most of it
would be tethered to the bound chemokine fraction (Figure 3). Furthermore, because the 1F11
antibody that was therapeutically effective in neutralizing the chemokine in vitro and in vivo had
been raised against the free (active) chemokine (and not the GAG-bound form), we concluded
that the free form should be targeted for therapeutic efficacy. Nature provides further support
for this observation in the guise of inhibitory chemokine-binding proteins produced by hema-
tophagous species, such as ticks. Although requiring full validation, preliminary results suggest
that evasins from hard ticks [33] are unable to interact with GAG-bound chemokines, yet might
be potent inhibitors of chemokine activity.
The Glycocalyx Barrier Represents a Conundrum for the ‘Bridge’ Model
As mentioned earlier, solution-phase chemokine concentrations cannot be maintained in the
vasculature due to high shear stress. Moreover, proteoglycans and their GAG chains are not
available as free and unrestricted cell surface molecular structures [34,35], a feature that has been
essentially ignored in current models and interpretations of chemokine presentation in the476 Trends in Immunology, June 2019, Vol. 40, No. 6
(A) (B)
Figure 3. Antibodies Targeting Glycosaminoglycan (GAG)-Bound Chemokines Are Ineffective. (A) Antibodies
(shown in green) that recognize GAG-bound chemokines (yellow) are ineffective in preventing recruitment because the
GAG-bound form effectively depletes most of the antibodies, leaving little to neutralize the active free form of the
chemokine. (B) The binding of antibodies (shown in blue) to solution-phase chemokines in the chemokine ‘cloud’ prevents
their interaction with receptors on leukocytes.leukocyte adhesion cascade. Instead, these highly sulfated and hydrated structures comprise
much of the glycocalyx, which covers vascular endothelial cell surfaces and shields the vascular
walls from direct exposure to blood flow [36]. The hydrated and continuous cell surface glycocalyx
layer is an irregularly shaped layer of variable thickness (up to 1.2 mm in microvascular mammalian
endothelial cells [37]) that extends into the lumen of blood vessels. Through interactions with the
GAG chains of proteoglycans, the glycocalyx sequesters a wide range of enzymes and proteins
(including chemokines) that contribute to regulating leukocyte adherence [37].
In the context of GAG–chemokine–receptor interactions, the glycocalyx presents a major
conundrum: on passing leukocytes, how do receptors that need to interact with integrin
ligands on cell surfaces find their way through this relatively thick glycocalyx layer? Additionally,
where on the GAG chains of the proteoglycans within the glycocalyx are chemokines pre-
sented? Are they presented at the top or the bottom of this layer, and what implications does
their location have for receptor activation and effective integrin–ligand interactions? How is the
active ‘free form’ of the chemokine stabilized within the glycocalyx, while still available to
receptors on the leukocyte surface, and to neutralizing antibodies?
Careful consideration of the constraints imposed by the glycocalyx along with insights from
studies of neutralizing antibodies as well as structural data, led us to propose a refinement of the
current ‘bridge’ model of chemokine presentation by GAGs to receptors on leukocytes.
Chemokine Interactions with GAGs and Receptors: A Refined Model
Our refined model takes into account all of the issues raised earlier and builds on the idea that
chemokines, oligomerized or not, are incapable of simultaneously binding to GAGs and
receptors. Instead, we propose that chemokines are initially trapped by GAGs in the glycocalyx
and then released in soluble form to receptors on leukocytes brought into close proximity byTrends in Immunology, June 2019, Vol. 40, No. 6 477
selectin interactions. The possibility of interstitial chemokines being presented to leukocytes
as a soluble ‘cloud’ was initially suggested in an Opinion article by others [38], and we adopt the
same terminology to describe our evidence-based refinement of this concept to the vasculature
[i.e., the ‘Cloud Model’ of chemokine presentation (Figure 4, Key Figure)]. The model encom-
passes concepts described here.
Chemokines Form a Soluble ‘Cloud’ within the Hydrated Glycocalyx Layer
Chemokine localization on GAGs is essential for their maintenance in the hydrated glycocalyx
on the luminal face of endothelial cells and in the presence of vascular shear flow. However, for
the reasons outlined earlier, GAG-bound chemokines cannot productively interact with their
cognate receptors; therefore, freely available, solution-phase, chemokines are the more likely
functional units. Why then, is there any requirement of GAGs for presentation of chemokines on
endothelial cells? We speculate that the primary role of GAGs is to concentrate chemokines in
localized depots near sites of production, particularly under conditions of infection or inflam-
mation. While this is not a new concept, what is new is the idea that these interactions may be
dynamic, with chemokines undergoing multiple rounds of binding, disengaging, and rebinding
to GAGs to form a ‘cloud’ of chemokines, effectively partitioned between GAGs and the
solution phase within the hydrated glycocalyx. The reversible binding dynamics of the chemo-
kines would enable them to be readily available upon release from GAG chains in order to
interact with receptors on passing leukocytes, but multiple cycles of rebinding to GAGs within
the glycocalyx would protect them from diffusing away due to shear stress. Direct evidence for
this is still required.Key Figure
The ‘Cloud’ Model of Receptor–Chemokine–Glycosaminoglycan (GAG)
Interactions
Figure 4. The model proposes that che-
mokines within the glycocalyx are present
in two forms; one form is bound to GAGs
and the other is present in solution phase
and comprises the chemokine ‘cloud’.
This distribution is achieved because che-
mokines are in equilibrium between the
GAG-bound and free form. This equili-
brium may facilitate the retention of che-
mokines in the glycocalyx by transient
interactions with GAGs, even in the pre-
sence of circulatory flow. It also provides a
mechanism for the free chemokine form
to bind to receptors on leukocytes.
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Outstanding Questions
Are solution-phase chemokines a pre-
ferred target for therapeutic antibody
development? Antichemokine anti-
bodies have failed in various clinical
trials. Would developing antibodies
against free, rather than GAG-bound,
chemokines be more effective?
How do receptors interpret multiple
chemokine cues in the glycocalyx? In
inflammation, numerous chemokines
are generated. It is not known how
these are presented and interpreted
by different receptors.
How do membrane-anchored chemo-
kines (e.g., CX3CL1) function within
the glycocalyx? Two members of
the chemokine family are not secreted
but are presented in a membrane-
anchored form. It remains unknown
how these function within the
glycocalyx.
What is the relevance of chemokine
oligomerization for function? Oligo-
merization is characteristic of inflam-
matory chemokines and enables
them to form depots bound to GAGs.
Does chemokine oligomerization have
other functions?
Integrins activated in response to
chemokine binding to receptors
have to interact with ligands on the
endothelial cell surface. How do
receptors bind ligands within the gly-
cocalyx to mediate integrin activa-
tion, as well as integrin–integrin
ligand interactions on endothelial
cells? This process may require
breaching the glycocalyx, and may
be mediated by filopodia extending
from the leukocyte surface.
How do selectins interact with their
ligands in the context of the glycoca-
lyx? As part of the leukocyte adhesion
cascade, selectins and their ligands
also interact on the endothelium. It is
unclear how this is achieved within the
glycocalyx.
Our model predicts the existence of
microgradients in the glycocalyx. Can
these be visualized and how do they
function?Chemokine Oligomerization May Amplify the Function of the Glycocalyx as a Chemokine
‘Sink’ and Source of the ‘Chemokine Cloud’
GAGs might act as a ‘sink’, maintaining chemokines in the glycocalyx through electrostatic
interactions between the negatively charged GAGs and the basic residues present on all
chemokines. Chemokine oligomerization likely plays a significant role in the retention and
dynamic release mechanism: multiple binding epitopes on chemokine oligomers and multiple
binding sites on GAGs may allow some subunits of the oligomers to disengage GAGs,
potentially becoming available to receptors, or to rebind GAGs instead of diffusing away.
Similarly, the density of GAG chains and of their chemokine binding epitopes may also
contribute to the ‘stickiness’ of the glycocalyx. In this way, a diffuse chemokine ‘cloud’ within
the hydrated glycocalyx layer could ideally provide a stable source of soluble chemokine, in
addition to a localized directional signal for cell migration.
The Glycocalyx May Support the Formation of Chemokine Microgradients
A microgradient directional signal of chemokines is favored by the production of chemokines
from endothelial cells themselves, or from underlying tissues, coupled with the transcytosis of
the cells to the luminal surface of the endothelium [39,40]. Thus, it is reasonable to speculate
that the concentration of chemokines bound to GAGs might be higher adjacent to the cell
surface, but lower at the outer reaches of the glycocalyx. While a vertical distribution of
chemokines within the glycocalyx has not yet been defined, if this holds true, this arrangement
might provide precisely localized microgradients of chemokines between cell surfaces and the
outer layers of the glycocalyx. This, in turn, might enable gradient-directed penetration of the
glycocalyx by receptor-bearing filopodia from leukocyte surfaces, in a manner analogous to
axonal pathfinding in the developing nervous system. Overall, the relative distribution of
chemokines within the glycocalyx might enable chemokine receptors and activated integrin-
bearing filopodia to find their way to endothelial cell surfaces, where essential integrin–integrin
ligand interactions and subsequent firm adhesion could then take place in the leukocyte
adhesion cascade.
Inflammatory Conditions May Favor Leukocyte Recruitment through Increased Partitioning
of Chemokines into the Soluble ‘Cloud’
Recent studies have shown that the density of GAG chains affects the affinity of chemokines
for GAGs [25,41,42]. Thus, changes in GAG density that alter the composition of the
glycocalyx may repartition chemokines between the bound and soluble phase. For example,
under certain inflammatory conditions, such as in a proximal microvessel occlusion ischemia
rat model [43], GAG chains can be shed from the glycocalyx due to induced expression of
proteolytic and GAG-degrading enzymes relative to controls [44]. This, in turn, may facilitate
the closer proximity of leukocytes to endothelial cell surfaces compared with steady-state
conditions [45,46]. A reduced density of GAG chains as a result of inflammation-mediated
shedding might favor the release of more chemokines into the solution-phase ‘cloud’,
subsequently becoming available for activating receptors to initiate the leukocyte adhesion
cascade.
Concluding Remarks
Here, we have presented a reconceptualized hypothetical ‘cloud’ model of chemokine pre-
sentation by GAGs in the leukocyte adhesion cascade. While this model remains speculative,
and requires further examination and robust testing, it ties together a large body of data related
to chemokine interactions with receptors and GAGs, and the dynamic properties of the
glycocalyx. If proven correct, this ‘cloud’ model could have important implications for the
development of therapeutic antichemokine antibodies or other direct antagonists of chemokineTrends in Immunology, June 2019, Vol. 40, No. 6 479
Is chemokine presentation on endo-
thelial cell surfaces different for inflam-
matory and homeostatic chemokines?
Does the inherent tendency of inflam-
matory chemokines to oligomerize
lead to a distinct presentation process
within the glycocalyx?function. Specifically, our model proposes that such therapeutics should be designed to
selectively target solution-phase chemokines (the ‘active’ form of chemokines that bind
receptors). Our model also suggests an explanation for the frequent reports of high concen-
trations of inflammatory chemokines in the circulation of patients with inflammatory diseases,
such as psoriasis [47,48] and rheumatoid arthritis [49,50]. We propose that elevated chemo-
kine concentrations might be a consequence of the ‘leaching’ of solution phase chemokines
from the glycocalyx cloud into the circulation, which, if correct, could provide a measure of the
extent of ongoing inflammation. Our model also provides a putative mechanism by which
chemokines, transported to the luminal face of endothelial cells through transcytosis [39], might
be presented to passing leukocytes in solution phase within the glycocalyx, and without the
requirement for transfer to GAGs. Many questions remain (see Outstanding Questions), but we
posit that the proposed ‘cloud’ model merits further investigation to refine our mechanistic
understanding of central aspects of tissue-specific leukocyte adhesion and migration in the
context of health and disease.
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